Better Coronavirus Stock: Novavax or Vaxart?
Both Moderna and Pfizer have brought coronavirus vaccines to market, but there still are plenty of opportunities to bet on players that haven't yet brought their vaccines across the finish line. I'm referring to companies that continue to study their candidates in clinical trials. Their shares could rise significantly if they report positive data and eventually win Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) are in just this situation.
Shares of these two clinical-stage biotech companies surged 2,600% and 1,500% respectively last year as they advanced their vaccine programs. In the fall, Novavax launched a phase 3 study, while Vaxart began its phase 1 trial. We can expect interim data from both companies soon.
But which is the better coronavirus stock to buy right now? Let's take a closer look at each.
Source Fool.com
